{"nctId":"NCT01005303","briefTitle":"Micronutrient Supplementation in Patients With Heart Failure","startDateStruct":{"date":"2009-02"},"conditions":["Heart Failure"],"count":79,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Micronutrient","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Forceval plus 50 micrograms Vitamin D3"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Forceval plus 50 micrograms Vitamin D3","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* New York Heart Association Class II and III\n* Already on or tried on best known medical treatment (ACE inhibitor and beta-blocker)\n* Stable for a period of at least 6 weeks\n* Left ventricular ejection fraction less than or equal to 45%\n\nExclusion Criteria:\n\n* History of significant alcohol ingestion (more than 40 units per week)\n* Severe renal dysfunction (GFR less than 30ml/min)\n* Severe hepatic dysfunction (known liver disease or transaminases greater than 3 times the upper limit of normal)\n* Atrial fibrillation (in the absence of a pacemaker)\n* Frequent ventricular ectopics\n* On waiting list for cardiac transplantation\n* Uncontrolled diabetes mellitus\n* Inability to give informed consent\n* Estimated life span less than 12 months\n* Already taking a multivitamin/mineral supplement\n* Already taking a vitamin-D containing fish oil\n* Woman of child-bearing potential\n* History of renal stones, hypercalcaemia, sarcoidosis, haemochromatosis or lactose intolerance","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Left Ventricular Ejection Fraction","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":"8.8"},{"groupId":"OG001","value":"38.9","spread":"11.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":"12.0"},{"groupId":"OG001","value":"38.6","spread":"10.9"}]}]}]},{"type":"SECONDARY","title":"Quality of Life Questionnaire Score","description":"Minnesota Living With Heart Failure Questionnaire. The questionnaire is comprised of 21 questions around several physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 (five) scale to indicate the extent to which each itemized adversity of heart failure has prevented the patient from living as they wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses (score range 0-105). Higher scores indicate worse quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":"25.2"},{"groupId":"OG001","value":"34.0","spread":"22.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.2","spread":"24.1"},{"groupId":"OG001","value":"33.1","spread":"21.6"}]}]}]},{"type":"SECONDARY","title":"Six Minute Walk Test Distance","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"437.8","spread":"94.9"},{"groupId":"OG001","value":"417.0","spread":"120.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"440.2","spread":"98.6"},{"groupId":"OG001","value":"412.5","spread":"114.9"}]}]}]},{"type":"SECONDARY","title":"Serum N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"841.6","spread":"1137.9"},{"groupId":"OG001","value":"1293.4","spread":"2064.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1343.6","spread":"2983.7"},{"groupId":"OG001","value":"1763.6","spread":"5024.5"}]}]}]},{"type":"SECONDARY","title":"Serum C-reactive Protein (CRP) Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"8.7"},{"groupId":"OG001","value":"6.3","spread":"15.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"3.8"},{"groupId":"OG001","value":"4.6","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Serum Tumor Necrosis Factor-alpha (TNF-α) Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"1.5"},{"groupId":"OG001","value":"4.1","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"1.6"},{"groupId":"OG001","value":"4.1","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Serum Interleukin-6 (IL-6) Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"6.5"},{"groupId":"OG001","value":"7.1","spread":"12.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"6.3"},{"groupId":"OG001","value":"4.2","spread":"3.8"}]}]}]},{"type":"SECONDARY","title":"Serum Interleukin-10 (IL-10) Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.1"},{"groupId":"OG001","value":"1.2","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.5"},{"groupId":"OG001","value":"1.1","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Urinary 8-iso-prostaglandin F2 Alpha (8-iso-PGF2α) Concentration","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":"5.8"},{"groupId":"OG001","value":"12.1","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"4.6"},{"groupId":"OG001","value":"10.5","spread":"3.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":36},"commonTop":[]}}}